Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Significance: Mucopolysaccharidosis type IIIB (MPS IIIB) is a devastating and currently untreatable disease affecting mainly the brain. The cause is lack of the lysosomal enzyme, α– N -acetylglucosaminidase (NAGLU), and storage of heparan sulfate. Using a mouse model of MPS IIIB, we administered a modified NAGLU by injection into the left ventricle of the brain, bypassing the blood–brain barrier. The modification consisted of a fragment of IGFII, which allows receptor-mediated uptake and delivery to lysosomes. The modified enzyme was taken up avidly by cells in both brain and liver, where it reduced pathological accumulation of heparan sulfate and other metabolites to normal or near-normal levels. The results suggest the possibility of treatment for MPS IIIB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at cerebrospinal fluid circulation
Brinker, T., Stopa, E., Morrison, J., & Klinge, P. (2014) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-11-10 · Cited by 819
Cited by
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Self-citationNeufeld, E. F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 900
Self-citationCSF, blood-brain barrier, and brain drug delivery
Pardridge, W. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1171315 · Cited by 508
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
“It is likely that IGFBP complex formation with either IGF1 or IGF2 blocks BBB transport of the peptide, because an IGF2-lysosomal enzyme fusion protein does not cross the BBB following IV administration (Kan et al., 2014).”
BackgroundA Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Metadata
- Authors
- Kan, S.-H., Aoyagi-Scharber, M., Le, S. Q., Vincelette, J., Ohmi, K., Bullens, S., Wendt, D. J., Christianson, T. M., Tiger, P. M. N., Brown, J. R., Lawrence, R., Yip, B. K., Holtzinger, J., Bagri, A., Crippen-Harmon, D., Vondrak, K. N., Chen, Z., Hague, C. M., Woloszynek, J. C., Cheung, D. S., Webster, K. A., Adintori, E. G., Lo, M. J., Wong, W., Fitzpatrick, P. A., LeBowitz, J. H., Crawford, B. E., Bunting, S., Dickson, P. I., & Neufeld, E. F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-09-29
- Volume
- 111
- Issue
- 41
- Pages
- 14870-14875
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2089713475
- Cited by
- 111
- References
- 1
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. https://app.cochat.ai/papers/10.1073/pnas.1416660111
- The paper
- Kan, S.-H., Aoyagi-Scharber, M., Le, S. Q., Vincelette, J., Ohmi, K., Bullens, S., Wendt, D. J., Christianson, T. M., Tiger, P. M. N., Brown, J. R., Lawrence, R., Yip, B. K., Holtzinger, J., Bagri, A., Crippen-Harmon, D., Vondrak, K. N., Chen, Z., Hague, C. M., Woloszynek, J. C., . . . Neufeld, E. F. (2014). Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1416660111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.